Neuroprotective effects of the α2-adrenoceptor antagonists, (+)- efaroxan and (±)-idazoxan, against quinolinic acid-induced lesions of the rat striatum

Experimental Neurology

Volumn 154, Issue 2, 1998, Pages 595-601

  Martel, J C ^a   Chopin, P ^a   Colpaert, F ^a   Marien, M ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Apomorphine induced circling; Choline acetyltransferase; Excitotoxicity; Huntington's disease; Neurodegenerative diseases; Quinolinic acid; Rat; Striatum; 2 adrenoceptor antagonists

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; CHOLINE ACETYLTRANSFERASE; DIZOCILPINE; EFAROXAN; EXCITOTOXIN; GLUTAMIC ACID; GROWTH FACTOR; IDAZOXAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORADRENALIN; QUINOLINIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BENZOFURAN DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; IMIDAZOLE DERIVATIVE; NEUROPROTECTIVE AGENT; NEUROTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DRUG EFFECT; GLIA CELL; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; DISEASE MODEL; ENZYME ACTIVATION; ENZYMOLOGY; HUNTINGTON CHOREA; METABOLISM; NERVE DEGENERATION; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; BENZOFURANS; CHOLINE O-ACETYLTRANSFERASE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; ENZYME ACTIVATION; HUNTINGTON DISEASE; IDAZOXAN; IMIDAZOLES; MALE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; NEUROTOXINS; QUINOLINIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 0032217094     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6942     Document Type: Article

References (65)

1. Albin R. L., Greenamyre T. J. Alternative excitotoxic hypothesis. Neurology. 42:1992;733-738.
2. Aoki C., Joh T. H., Pickel V. M. Ultrastructural localization of β-adrenergic receptor-like immunoreactivity in the cortex and neostriatum of rat brain. Brain Res. 437:1987;264-282.
3. Beal M. F., Hyman B. T., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases. Trends Neurosci. 16:1993;125-131.
4. Beal M. F. Role of excitotoxicity in human neurological disease. Curr. Opin. Neurobiol. 2:1992;657-662.
5. Bickler P. E., Hansen B. M. α2-Adrenergic agonists reduce glutamate release and glutamate receptor-mediated calcium changes in hippocampal slices during hypoxia. Neuropharmacology. 35:1996;679-687.
6. Bing G., Zhang Y., Watanabe Y., McEwen B. S., Stone E. A. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 668:1994;261-265.
7. Bockaert J., Homburger V., Sladeczec F. Molecular pharmacology of adrenergic receptors and their cellular localization in brain cells in culture. The Pharmacology of Noradrenaline in the Central Nervous System. 1990;Oxford Univ. Press. p. 76-117.
8. Bullock R. Strategies for neuroprotection with glutamate antagonists-extrapolating from evidence taken from the first stroke and head injury studies. Ann. NY Acad. Sci. 765:1995;272-278.
9. Carter C. J., Gueugnon J., Scatton B. Noradrenaline antagonizes and ouabain potentiates the effects ofND. J. Neurochem. 51:1988;944-949.
10. Choi D. W. Excitotoxic cell death. J. Neurobiol. 23:1992;1261-1276.
11. Colpaert F. Effects of putative α-adrenoceptor antagonists and of other compounds on the loss of the righting reflex and on exophthalmia induced by xylazine in the rat. Drug Dev. Res. 7:1986;125-140.
12. Colpaert F. C. Noradrenergic mechanisms in Parkinson's disease: A theory. Briley M., Marien M. Noradrenergic Mechanisms in Parkinson's Disease. 1994;225-254 CRC Press, Boca Raton.
13. Crowder J. M., Bradford H. F. Inhibitory effects of noradrenaline and dopamine on calcium influx and neurotransmitter glutamate release in mammalian brain slices. Eur. J. Pharmacol. 143:1987;343-352.
14. Davis J. N., Nishino K., Moore K. Noradrenergic regulation of delayed neuronal death after transient forebrain ischemia. Ginsberg M. D., Dietrich D. Cerebrovascular Diseases. 1989;109-115 Raven Press.
15. Dennis T., L'Heureux R., Carter C., Scatton B. Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured byin vivo. J. Pharmacol. Exp. Ther. 241:1987;642-649.
16. Dodt H.-U., Pawelzik H., Zieglgansberger W. Actions of noradrenaline on neocortical neurons in vitro. Brain Res. 545:1991;307-311.
17. Doxey J. C., Roach A. G., Smith C. F. C. Studies on RX 781094: A selective, potent and specific antagonist of α2-adrenoceptors. Br. J. Pharmacol. 78:1983;489-505.
18. Eddleston M., Mucke L. Molecular profile of reactive astrocytes-implication for their role in neurologic disease. Neuroscience. 54:1993;15-36.
19. Feinstein D. L., Galea E., Reis D. J. Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J. Neurochem. 60:1993;1945-1948.
20. Flamez A., De Backer J.-P., Czerwiec E., Ladure P., Vauquelin G. Pharmacological characterization of I1 and I2 imidazoline receptors in human striatum. Neurochem. Int. 30:1997;25-29.
21. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24:1975;407-409.
22. French N. α2-Adrenoceptors and I2 sites in the mammalian central nervous system. Pharmacol. Ther. 68:1995;175-208.
23. Garside S., Furtado J. C. S., Mazurek M. F. Dopamine-glutamate interactions in the striatum: behaviourally relevant modification of excitotoxicity by dopamine receptor-mediated mechanisms. Neuroscience. 75:1996;1065-1074.
24. Griffith R., Sutin J. Reactive astrocyte formationin vivo. J. Comp. Neurol. 371:1996;362-375.
25. Gustafson I., Miyauchi Y., Wieloch T. W. Postischemic administration of idazoxan, an α-2 adrenergic receptor antagonist, decreases neuronal damage in the rat brain. J. Cereb. Blood Flow Metab. 9:1989;171-174.
26. Gustafson I., Wasterberg E., Wieloch T. Protection against ischemia-induced neuronal damage by the a2-adrenoceptor antagonist idazoxan: influence of time of administration and possible mechanisms of action. J. Cereb. Blood Flow Metab. 10:1990;885-894.
27. Gustafson, I. 1991, Cerebral Ischemia and the Central Noradrenergic System in the Rat, University of Lund, Lund, Sweden.
28. Hanson E., Ronnback L. Adrenergic receptor regulation of amino acid neurotransmitter uptake in astrocytes. Brain Res. Bull. 29:1992;297-301.
29. Hertz L. Autonomic control of neuronal-astrocytic interactions, regulating metabolic activities and ion fluxes in the CNS. Brain Res. Bull. 29:1992;305-313.
30. Hoogendijk W. J. G., Pool C. W., Troost D., Van Zwieten E., Swaab D. F. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain. 118:1995;131-143.
31. 3. Mol. Neuropharmacol. 1:1992;219-229.
32. Iversen L. L. MK-801 (dizocilpine maleate) - NMDA receptor antagonist. Neurotransmission. 10:1994;1-4.
33. Keilhoff G., Wolf G., Stastny F., Schmidt W. Quinolinate neurotoxicity and glutamatergic structures. Neuroscience. 34:1990;235-242.
34. Koroshetz W. J., Jenkins B. G., Rosen B. R., Beal M. F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41:1997;160-165.
35. Lipton S. A., Rosenberg P. A. Excitatory amino acids as a final common pathway for neurologic disorders. New Engl. J. Med. 330:1994;613-622.
36. Lowry O. H., Rosenbrough N. J., Farr A. L., Randall R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
37. Marien M., Briley M., Colpaert F. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol. 236:1993;487-489.
38. 2. Soc. Neurosci. Abstr. 22:1996;1908.
39. Mavridis M., Degryse A.-D., Lategan A. J., Marien M. R., Colpaert F. C. Effect of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience. 41:1991;507-523.
40. Meldrum B. Protection against ischemic neuronal damage by drugs acting on excitatory neurotransmission. Cerebrovasc. Brain Metab. Rev. 2:1990;27-57.
41. alpha-2A. J. Pharmacol. Exp. Ther. 270:1994;958-972.
42. Miyamoto M., Coyle J. T. Ibedenone attenuates neuronal degeneration induced by striatal injection of excitotoxins. Exp. Neurol. 108:1990;38-45.
43. Guide for the Care and Use of Laboratory Animals. 1996;National Acad. Press, Washington.
44. Olmos G., Ribera J., García-Sevilla J. A. Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the brain. Eur. J. Pharmacol. 310:1996;273-276.
45. Olney J. W. Excitotoxic amino acids and neuropsychiatric disorders. Annu. Rev. Pharmacol. Toxicol. 30:1990;47-71.
46. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, Sidney.
47. Pérez-Navarro E., Alberch J., Arenas E., Calvo N., Marsal J. Nerve growth factor and basic fibroblast growth factor protect cholinergic neurons against quinolinic acid excitotoxicity in the rat neostriatum. Eur. J. Pharmacol. 6:1994;706-711.
48. alpha2Aalpha2A. J. Pharmacol. Exp. Ther. 270:1994;946-957.
49. Rothman S. M., Olney J. W. Excitotoxicity and the NMDA receptor - Still lethal after eight years. Trends Neurosci. 18:1995;57-58.
50. Salm A. K., McCarthy K. D. The evidence for astrocytes as a target for central noradrenergic activity: Expression of adrenergic receptors. Brain Res. Bull. 29:1992;265-275.
51. Schapira A. H. V. Evidence for mitochondrial dysfunction in Parkinson's disease - A critical appraisal. Mov. Disord. 9:1994;125-138.
52. Schapira A. H. V. Mitochondrial function in Huntington's disease: Clues for pathogenesis and prospects for treatment. Ann. Neurol. 41:1997;141-142.
53. Schwarcz R., Foster A. C., French E. D., Whetsell W. O., Kohler C. II. Excitotoxic models for neurodegenerative disorders. Life Sci. 35:1984;19-32.
54. Schwartz J. P., Costa E. Regulation of nerve growth factor content in C6 glioma cells by β-adrenergic receptor stimulation. Naunyn-Schmiedeberg's Arch. Pharmacol. 300:1977;123-129.
55. Schwartz J. P., Mishler K. Beta-adrenergic regulation, through cyclic AMP, of nerve growth factor expression in rat cortical and cerebellar astrocytes. Cell. Mol. Neurobiol. 10:1990;447-457.
56. Stone E. A., Ariano M. A. Are glial cells targets of the central noradrenergic system? A review of the evidence. Brain Res. Rev. 14:1989;297-309.
57. Stone E. A., Manavalan J. S., Basham D. A., Bing G. Effect of yohimbine on nerve growth factor mRNA and protein levels in rat hippocampus. Neurosci. Lett. 167:1994;11-13.
58. Stone T. W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45:1993;309-379.
59. Susel Z., Engber T. M., Chase T. N. Behavioral evaluation of the antiexcitotoxic properties of MK-801: Comparison with neurochemical measurements. Neurosci. Lett. 104:1989;125-129.
60. Tsacopoulos M., Magistretti P. J. Metabolic coupling between glia and neurons. J. Neurosci. 16:1996;877-885.
61. Turski L., Turski W. A. Towards an understanding of glutamate in neurodegenerative disorders: Energy metabolism and neuropathology. Experientia. 49:1993;1064-1072.
62. Ungerstedt U., Arbuthnott G. W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
63. van Veldhuizen M. J., Feenstra M. G., Boer G. J. Regional differences in thein vivo. Brain Res. 635:1994;238-248.
64. van Veldhuizen M. J., Feenstra M. G., Botterblom M. H., Boer G. J. In vivo. Br. J. Pharmacol. 109:1993;655-660.
65. Zhang K.-M., Wang X.-M., Paterson A. M., Brown D. E., Chen W. Y., Mokha S. S. Adrenoceptors (α2) modulate NMDA-evoked responses of neurons in the medullary dorsal horn. Soc. Neurosci. Abstr. 22:1996;1360.